Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Joo, Kwon Wook ^a,b   Kim, Sejoong ^c   Ahn, Shin Young ^c   Chin, Ho Jun ^b,c   Chae, Dong Wan ^b,c   Lee, Jeonghwan ^a   Han, Jin Suk ^a,b   Na, Ki Young ^b,c  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Dipeptidyl peptidase IV; FoxO3a; Glucagon like peptide 1 receptor; Kidney injury; Sitagliptin

Indexed keywords

CASPASE 3; CASPASE 9; CATALASE; CREATININE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN KINASE B; SITAGLIPTIN; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CELL INFILTRATION; CREATININE BLOOD LEVEL; DISEASE SEVERITY; ENZYME ACTIVITY; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; INTERSTITIAL NEPHRITIS; MACROPHAGE; MALE; NEPHRECTOMY; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

ACUTE KIDNEY INJURY; ANIMALS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FORKHEAD TRANSCRIPTION FACTORS; KIDNEY; MALE; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; TRIAZOLES;

EID: 84876694846     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-98     Document Type: Article

References (41)

1. Biology of incretins: GLP-1 and GIP. Baggio LL, Drucker DJ, Gastroenterology 2007 132 2131 2157 10.1053/j.gastro.2007.03.054 17498508 (Pubitemid 46711096)
2. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Mentlein R, Regul Pept 1999 85 9 24 10.1016/S0167-0115(99)00089-0 10588446 (Pubitemid 29505281)
3. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Drucker DJ, Nauck MA, Lancet 2006 368 1696 1705 10.1016/S0140-6736(06)69705-5 17098089 (Pubitemid 46048557)
4. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, Chang YS, J Am Soc Nephrol 2007 18 1227 1238 10.1681/ASN. 2006070778 17360951 (Pubitemid 46536909)
5. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H, Diabetologia 2011 54 965 978 10.1007/s00125-010-2028-x 21253697
6. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Mega C, de Lemos ET, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, Teixeira F, Reis F, Exp Diabetes Res 2011 10.1155/2011/162092
7. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS, J Pharmacol Exp Ther 2012 340 248 255 10.1124/jpet.111.186866 22025647
8. DPP4 inhibition improves functional outcome after renal ischemia reperfusion injury. Glorie LL, Verhulst A, Matheeussen V, Baerts L, Magielse J, Hermans N, D'Haese PC, De Meester I, De Beuf A, Am J Physiol Renal Physiol 2012 303 681 F688 10.1152/ajprenal.00075.2012 22718884
9. A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles. Lim SB, Rubinstein I, Sadikot RT, Artwohl JE, Önyüksel H, Pharm Res 2011 28 662 672 10.1007/s11095-010-0322-4 21108040
10. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Jungraithmayr W, De Meester I, Matheeussen V, Baerts L, Arni S, Weder W, Eur J Cardiothorac Surg 2012 41 1166 1173 10.1093/ejcts/ezr180 22219460
11. Primary graft dysfunction in lung transplantation: the role of CD26/dipeptidylpeptidase IV and vasoactive intestinal peptide. Zhai W, Jungraithmayr W, De Meester I, Inci I, Augustyns K, Arni S, Hillinger S, Scharpé S, Weder W, Korom S, Transplantation 2009 87 1140 1146 10.1097/TP.0b013e31819e04c3 19384159
12. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ, Diabetes 2009 58 975 983 10.2337/db08-1193 19151200
13. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Sauvé M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, Drucker DJ, Diabetes 2010 59 1063 1073 10.2337/db09-0955 20097729
14. Pathophysiology of progressive nephropathies. Remuzzi G, Bertani T, N Engl J Med 1998 339 1448 1456 10.1056/NEJM199811123392007 9811921 (Pubitemid 28516069)
15. Animal models of FSGS: lessons for pathogenesis and treatment. Fogo AB, Semin Nephrol 2003 23 161 171 10.1053/snep.2003.50015 12704576 (Pubitemid 36397098)
16. Akt, FoxO and regulation of apoptosis. Zhang X, Tang N, Hadden TJ, Rishi AK, Biochim Biophys Acta 1813 2011 1978 1986
17. FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Tzivion G, Dobson M, Ramakrishnan G, Biochim Biophys Acta 1813 2011 1938 1945
18. FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics. Jacobs FM, van der Heide LP, Wijchers PJ, J Biol Chem 2003 278 35959 35967 10.1074/jbc.M302804200 12857750 (Pubitemid 37139914)
19. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA, Clin Ther 2006 28 55 72 10.1016/j.clinthera.2006.01.015 16490580 (Pubitemid 43254990)
20. Glucagonlike peptide I (7-37) actions on endocrine pancreas. Weir GC, Mojsov S, Hendrick GK, Habener JF, Diabetes 1989 38 338 342 10.2337/diabetes.38. 3.338 2645190 (Pubitemid 19071474)
21. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Schlatter P, Beglinger C, Drewe J, Gutmann H, Regul Pept 2007 141 120 128 10.1016/j.regpep.2006.12.016 17276524 (Pubitemid 46482693)
22. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. Chaykovska L, von Websky K, Rahnenführer J, Alter M, Heiden S, Fuchs H, Runge F, Klein T, Hocher B, PLoS One 2011 6 27861 10.1371/journal.pone.0027861 22125632
23. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. Lim S, Choi SH, Shin H, Cho BJ, Park HS, Ahn BY, Kang SM, Yoon JW, Jang HC, Kim YB, Park KS, PLoS One 2012 7 35007 10.1371/journal.pone.0035007 22493727
24. FoxO1 haploinsufficiency protects against high-fat diet-induced insulin resistance with enhanced peroxisome proliferator-activated receptor gamma activation in adipose tissue. Kim JJ, Li P, Huntley J, Chang JP, Arden KC, Olefsky JM, Diabetes 2009 58 1275 1282 10.2337/db08-1001 19289458
25. Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription. Fang CX, Dong F, Thomas DP, Ma H, He L, Ren J, Am J Physiol Heart Circ Physiol 2008 295 1206 H1215 10.1152/ajpheart.00319.2008 18641278
26. The role of incretins in glucose homeostasis and diabetes treatment. Kim W, Egan JM, Pharmacol Rev 2008 60 470 512 10.1124/pr.108.000604 19074620
27. Obesity and hypertension have differing oxidant handling molecular pathways in age-related chronic kidney disease. Percy CJ, Brown L, Power DA, Johnson DW, Gobe GC, Mech Ageing Dev 2009 130 129 138 10.1016/j.mad.2008.10.003 19041334
28. High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α pathway. Chung HW, Lim JH, Kim MY, Shin SJ, Chung S, Choi BS, Kim HW, Kim YS, Park CW, Chang YS, Nephrol Dial Transplant 2012 27 2213 2225 10.1093/ndt/gfr613 22076434
29. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Vaziri ND, Oveisi F, Ding Y, Kidney Int 1998 53 1748 1754 10.1046/j.1523-1755.1998.00947.x 9607208 (Pubitemid 28243760)
30. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. Miyata T, Kurokawa K, Van Ypersele De Strihou C, J Am Soc Nephrol 2000 11 1744 1752 10966500
31. Superoxide radical and superoxide dismutases. Fridovich I, Annu Rev Biochem 1995 64 97 112 10.1146/annurev.bi.64.070195.000525 7574505
32. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ, J Biol Chem 2003 278 471 478 12409292 (Pubitemid 36043598)
33. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN, Nat Med 2003 9 1173 1179 10.1038/nm919 12925848 (Pubitemid 37173702)
34. Protection of exendin-4 analogue in early experimental diabetic retinopathy. Zhang Y, Wang Q, Zhang J, Lei X, Xu GT, Ye W, Graefes Arch Clin Exp Ophthalmol 2009 247 699 706 10.1007/s00417-008-1004-3 19084986
35. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, Fava G, Francis H, Trozzi L, Benedetti A, Gut 2009 58 990 997 10.1136/gut.2008.150870 18829977
36. Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42). Qin Z, Sun Z, Huang J, Hu Y, Wu Z, Mei B, Neurosci Lett 2008 444 217 221 10.1016/j.neulet.2008.08.047 18760331
37. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Liu JH, Yin F, Guo LX, Deng XH, Hu YH, Acta Pharmacol Sin 2009 30 159 165 10.1038/aps.2008.25 19151742
38. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Kimura R, Okouchi M, Fujioka H, Ichiyanagi A, Ryuge F, Mizuno T, Imaeda K, Okayama N, Kamiya Y, Asai K, Joh T, Neuroscience 2009 162 1212 1219 10.1016/j.neuroscience.2009.05.025 19463904
39. GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. Quoyer J, Longuet C, Broca C, Linck N, Costes S, Varin E, Bockaert J, Bertrand G, Dalle S, J Biol Chem 2010 285 1989 2002 10.1074/jbc.M109.067207 19915011
40. Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Ravassa S, Zudaire A, Carr RD, Díez J, Am J Physiol Heart Circ Physiol 2011 300 1361 H1372 10.1152/ajpheart.00885.2010 21278133
41. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H, Diabetes 2010 59 1030 1037 10.2337/db09-1694 20068138